CL2021001044A1 - Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrización de heridas y la recuperación posoperatoria - Google Patents

Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrización de heridas y la recuperación posoperatoria

Info

Publication number
CL2021001044A1
CL2021001044A1 CL2021001044A CL2021001044A CL2021001044A1 CL 2021001044 A1 CL2021001044 A1 CL 2021001044A1 CL 2021001044 A CL2021001044 A CL 2021001044A CL 2021001044 A CL2021001044 A CL 2021001044A CL 2021001044 A1 CL2021001044 A1 CL 2021001044A1
Authority
CL
Chile
Prior art keywords
plasma
wound healing
postoperative recovery
fractions
improve pain
Prior art date
Application number
CL2021001044A
Other languages
English (en)
Inventor
Ian Gallager
Marian Castro
Viktoria Kheifets
benson Lu
Original Assignee
Alkahest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkahest Inc filed Critical Alkahest Inc
Publication of CL2021001044A1 publication Critical patent/CL2021001044A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Se describen métodos y composiciones para mejorar la recuperación posoperatoria. Las composiciones utilizadas en los métodos incluyen plasma sanguíneo y fracciones de plasma sanguíneo derivadas de plasma sanguíneo con eficacia para tratar y/o prevenir afecciones asociadas con la recuperación posoperatoria.
CL2021001044A 2018-10-26 2021-04-23 Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrización de heridas y la recuperación posoperatoria CL2021001044A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862751448P 2018-10-26 2018-10-26
US201962842403P 2019-05-02 2019-05-02

Publications (1)

Publication Number Publication Date
CL2021001044A1 true CL2021001044A1 (es) 2021-11-26

Family

ID=70327508

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001044A CL2021001044A1 (es) 2018-10-26 2021-04-23 Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrización de heridas y la recuperación posoperatoria

Country Status (14)

Country Link
US (5) US11103530B2 (es)
EP (1) EP3870190A4 (es)
JP (1) JP2022505915A (es)
KR (1) KR20210068573A (es)
CN (1) CN113056275A (es)
AU (1) AU2019364271A1 (es)
BR (1) BR112021006743A2 (es)
CA (1) CA3115308A1 (es)
CL (1) CL2021001044A1 (es)
IL (1) IL282227B1 (es)
MX (1) MX2021004755A (es)
SG (1) SG11202103696XA (es)
TW (1) TWI819129B (es)
WO (1) WO2020086469A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113056275A (zh) * 2018-10-26 2021-06-29 万能溶剂有限公司 血浆和血浆组分用于改善疼痛、伤口愈合和术后恢复的用途
AU2020378245A1 (en) 2019-11-04 2022-04-07 Alkahest, Inc. Blood plasma fractions for use in muscle regeneration
US11484551B2 (en) * 2019-11-20 2022-11-01 Alkahest, Inc. Method of treating liver failure with plasma fraction IV-4
AU2020388572A1 (en) 2019-11-20 2022-05-26 Alkahest, Inc. Blood plasma fractions for use in liver regeneration

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4075197A (en) 1976-09-20 1978-02-21 Monsanto Company Serum albumin production
JPS60154150A (ja) 1984-01-25 1985-08-13 Hitachi Ltd 電気泳動装置
US4708713A (en) 1984-11-16 1987-11-24 Anisa Medical, Inc. Method and system for removing immunosuppressive components from the blood of mammals
DE3612137A1 (de) 1986-04-10 1987-10-15 Biotest Pharma Gmbh Steriles plasmaaustauschmittel
US5792835A (en) 1991-09-05 1998-08-11 Baxter International Inc. Method of preparing a topical fibrinogen complex
US6544761B2 (en) 1994-12-13 2003-04-08 Human Genome Sciences, Inc. Human tissue inhibitor of metalloproteinase-4
US5916202A (en) 1996-08-30 1999-06-29 Haswell; John N. Umbilical cord blood collection
US6416487B1 (en) 1997-07-30 2002-07-09 Renal Tech International Llc Method of removing beta-2 microglobulin from blood
UA35656C2 (uk) 1999-12-27 2001-04-16 Олександр Миколайович Макаренко Спосіб лікування безперервно прогредієнтних ослабоумлюючих психічних захворювань
US6946546B2 (en) 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
US6632174B1 (en) 2000-07-06 2003-10-14 Cognifit Ltd (Naiot) Method and apparatus for testing and training cognitive ability
US20020151064A1 (en) 2001-02-07 2002-10-17 Children's Hospital Medical Center Regulation of CCR3 expression
US6811777B2 (en) * 2002-04-13 2004-11-02 Allan Mishra Compositions and minimally invasive methods for treating incomplete connective tissue repair
JP2005530768A (ja) * 2002-05-09 2005-10-13 メディジーンズ 血漿または血清を含有した創傷治療用医薬組成物
JP2004051023A (ja) * 2002-07-22 2004-02-19 Toyota Motor Corp 車両の制御装置
US20040127445A1 (en) 2002-08-28 2004-07-01 Chondrogene Limited Beta-2 microglobulin (B2M) and B2M related gene products for the regulation of osteoarthritis pathogenesis and chondrocyte proliferation
US20040120937A1 (en) 2002-12-19 2004-06-24 Therapy Patent Corporation Blood therapy process
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US20040146565A1 (en) * 2003-01-28 2004-07-29 Lauridsen Group Incorporated First lipoprotein fraction and therapeutic compositions of same
GB0305133D0 (en) 2003-03-06 2003-04-09 Sinvent As Product
WO2004084898A1 (en) 2003-03-24 2004-10-07 Actimis Pharmaceuticals, Inc. 2-phenoxy- and 2-phenylsulfomamide derivatives with ccr3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders
EP1622577A4 (en) 2003-04-17 2007-09-26 Univ Leland Stanford Junior PREVENTION OF DEFICIT NEUROGENESIS DISORDERS WITH ANTI-INFLAMMATORY AGENTS
US7598049B2 (en) 2003-11-19 2009-10-06 Satoris, Inc. Methods for diagnosis of Alzheimer's Disease in blood samples
US20060094064A1 (en) 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
WO2005106492A2 (en) 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 3 (ccr3)
TW200635607A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized Aβ antibodies for use in improving cognition
CA2597431A1 (en) * 2005-02-11 2006-08-17 Cambridge Scientific Pty Ltd A method of producing an analgesic composition from plasma or serum and use in treating pain
KR100782333B1 (ko) * 2005-08-11 2007-12-06 메디제네스(주) 혈장 또는 혈청을 포함하는 신경손상 치료용 약학 조성물
US20070048387A1 (en) 2005-09-01 2007-03-01 Edwards Jeffrey D Tissue disruption treatment and composition for use thereof
US20090181008A1 (en) 2005-11-10 2009-07-16 Satoris, Inc. Methods of treating alzheimer's disease
US10344095B2 (en) 2006-02-16 2019-07-09 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
JP2009149524A (ja) 2006-03-16 2009-07-09 Kyushu Univ アルツハイマー病の予防・治療剤
EP2008100A4 (en) 2006-04-18 2009-12-16 Univ Leland Stanford Junior ESTABLISHING ANTIBODY PROFILES FOR DETERMINING PATIENT SENSITIVITY TO TREATMENT
KR20070113876A (ko) * 2006-05-26 2007-11-29 메디제네스(주) 혈장성분을 함유하는 창상 치료용 약학 조성물
EP2302395B1 (en) 2006-06-07 2015-04-15 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
US7592009B2 (en) 2006-10-10 2009-09-22 Ecole Polytechnique Federale De Lausanne (Epfl) Polypeptide ligands for targeting cartilage and methods of use thereof
WO2009023814A2 (en) 2007-08-15 2009-02-19 University Of South Florida Hucbc treatment of amyloid associated disease
US8097645B2 (en) 2007-10-12 2012-01-17 The Board Of Trustees Of The Leland Stanford Junior University Compounds for activating TGF-β signaling
US20090227018A1 (en) 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US20100310609A1 (en) 2007-10-25 2010-12-09 Revalesio Corporation Compositions and methods for treatment of neurodegenerative diseases
ES2332846B1 (es) 2007-10-26 2010-07-08 Grifols, S.A. Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.
US9616393B2 (en) 2007-12-06 2017-04-11 Asahi Kasei Medical Co., Ltd. Porous hollow fiber membrane for treating blood
US20100124756A1 (en) 2008-10-10 2010-05-20 Sandip Ray Collection of biomarkers for diagnosis and monitoring of alzheimer's disease in body fluids
US20110117100A1 (en) 2008-11-03 2011-05-19 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for diagnosis, stratification and treatment of amyloidogenic diseases
AT514675B1 (de) 2009-07-23 2019-05-15 Baxalta Inc Herstellung von faktor h (fh) und fh-derivaten aus plasma
CN201453773U (zh) * 2009-08-04 2010-05-12 侯涛 血浆专用注射器
US10626399B2 (en) 2010-01-28 2020-04-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3)
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
WO2011094535A2 (en) 2010-01-28 2011-08-04 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers of aging for detection and treatment of disorders
US20110202284A1 (en) 2010-02-10 2011-08-18 Mcreynolds Cristopher Novel groups of biomarkers for diagnosing alzheimer's disease
RU2428997C1 (ru) 2010-03-01 2011-09-20 Федеральное государственное образовательное учреждение высшего профессионального образования Волгоградская государственная сельскохозяйственная академия Способ получения лечебных препаратов из пуповины плода
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
US8206715B2 (en) 2010-05-04 2012-06-26 Five Prime Therapeutics, Inc. Antibodies that bind colony stimulating factor 1 receptor (CSF1R)
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
RU2470677C1 (ru) 2011-10-19 2012-12-27 Надежда Михайловна Цулая Способ стимуляции репаративных и трофических процессов в коже
US20150079045A1 (en) 2012-02-13 2015-03-19 Wuyi Kong Nprcps, pfdncs and uses thereof
IN2014MN02089A (es) 2012-03-20 2015-09-11 Einstein Coll Med
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US9512052B2 (en) 2012-10-29 2016-12-06 China Petroleum & Chemical Corporation Adsorption desulfurization process for hydrocarbons and a reaction apparatus therefor
WO2015088915A1 (en) 2013-12-09 2015-06-18 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated conditions
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
CN116687969A (zh) 2015-05-18 2023-09-05 小利兰·斯坦福大学托管委员会 用于治疗衰老相关的损伤的方法和组合物
ES2902467T3 (es) 2015-06-15 2022-03-28 Univ Leland Stanford Junior TIMP2 para su uso en el tratamiento de afecciones asociadas al envejecimiento
ES2887588T3 (es) * 2015-08-13 2021-12-23 Kamada Ltd Composiciones derivadas de pasta de fracción de Cohn y uso de las mismas
RS62558B1 (sr) * 2016-08-18 2021-12-31 Alkahest Inc Frakcije krvne plazme kao terapija za kognitivne poremećaje povezane sa starenjem
US10525107B2 (en) * 2016-08-18 2020-01-07 Alkahest, Inc. Blood plasma fractions as a treatment for aging-associated cognitive disorders
KR20190135059A (ko) * 2017-04-26 2019-12-05 알카헤스트 인코포레이티드 혈장 및 혈장 산물로 인지 및 운동 장애를 치료하기 위한 투여 요법
CN113056275A (zh) * 2018-10-26 2021-06-29 万能溶剂有限公司 血浆和血浆组分用于改善疼痛、伤口愈合和术后恢复的用途

Also Published As

Publication number Publication date
US11103530B2 (en) 2021-08-31
AU2019364271A1 (en) 2021-06-03
BR112021006743A2 (pt) 2021-07-13
US11547724B2 (en) 2023-01-10
US20230111752A1 (en) 2023-04-13
US11298377B2 (en) 2022-04-12
MX2021004755A (es) 2021-06-08
EP3870190A4 (en) 2022-09-07
EP3870190A1 (en) 2021-09-01
US20200129549A1 (en) 2020-04-30
US20230285455A1 (en) 2023-09-14
TW202029970A (zh) 2020-08-16
IL282227A (en) 2021-05-31
JP2022505915A (ja) 2022-01-14
CA3115308A1 (en) 2020-04-30
TWI819129B (zh) 2023-10-21
US20210106616A1 (en) 2021-04-15
IL282227B1 (en) 2024-04-01
CN113056275A (zh) 2021-06-29
KR20210068573A (ko) 2021-06-09
WO2020086469A1 (en) 2020-04-30
US20200129550A1 (en) 2020-04-30
SG11202103696XA (en) 2021-05-28

Similar Documents

Publication Publication Date Title
CL2021001044A1 (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrización de heridas y la recuperación posoperatoria
CL2021003477A1 (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CL2021003196A1 (es) Terapias combinadas dirigidas a pd-1, tim-3, y lag-3 (divisional de solicitud n° 201902850)
UY38403A (es) Moduladores de la alfa-1 antitripsina
CL2020003257A1 (es) Compuestos antagonistas de pcsk9.
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
CY1121997T1 (el) Κρυσταλλικες μορφες του 2-((4s)-6-(4-χλωροφαινυλ)-1-μεθυλ-4η-βενζο[c]ισοξαζολo[4,5-ε]αζεπιν-4-υλ)ακεταμιδιου
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
CL2019000304A1 (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
MX2020003959A (es) Metodos terapeuticos relacionados con los inhibidores de hsp90.
BR112015024234A2 (pt) composição de liberação sustentada injetável e método para o uso da mesma para tratar inflamação em articulações e dor associada com a mesma
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
CO2022000481A2 (es) Inhibidores de enzimas
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
BR112022008558A2 (pt) Método de tratamento para câncer, tratamento de combinação de nivolumabe e anticorpos anti-pvrig, e, uso
CL2020003380A1 (es) Compuestos que aumentan la actividad del proteosoma.
MX2019001633A (es) Proteina derivada de la seda para el tratamiento de la inflamacion.
CL2021000129A1 (es) Apirasas solubilizadas, métodos y usos
CO2021006480A2 (es) Inhibidores de rip1
ECSP20082339A (es) Moduladores de la expresión de apol1